drugset / Trial / NCT04258462
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
Phase 2
Active not recruiting
54 enrolled
Zhen Wang, MD
American Cancer Society, Inc. · collabNational Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
This feasibility study will evaluate how well hyperpolarized 13C pyruvate magnetic resonance imaging (MRI) scan works in predicting tumor aggressiveness in participants with renal tumors. Hyperpolarized 13C pyruvate is a non-radioactive substance with potential usage in the diagnostic imaging of tumors. Hyperpolarized 13C pyruvate MRI may help doctors determine non-invasively whether a kidney tumor is a benign tumor or cancer, and if cancer, how aggressive it is. This may help doctors and participants with renal tumors in the future to make better treatment decisions.
Timeline
- Start
- 2019-01-15
- Primary completion
- 2026-10-31
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hyperpolarized 13C,15N2-urea | Diagnostic / imaging agent | — | Intravenous |
| Subject | Hyperpolarized 13C-Pyruvate | Diagnostic / imaging agent | — | Intravenous |